39.14
-0.25 (-0.63%)
Previous Close | 39.39 |
Open | 39.31 |
Volume | 2,054,169 |
Avg. Volume (3M) | 421,401 |
Market Cap | 1,881,905,920 |
Price / Earnings (TTM) | 13.00 |
Price / Sales | 2.69 |
Price / Book | 2.45 |
52 Weeks Range | |
Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
Profit Margin | 21.80% |
Operating Margin (TTM) | 29.83% |
Diluted EPS (TTM) | 3.01 |
Quarterly Revenue Growth (YOY) | 5.90% |
Quarterly Earnings Growth (YOY) | -17.90% |
Total Debt/Equity (MRQ) | 86.56% |
Current Ratio (MRQ) | 3.43 |
Operating Cash Flow (TTM) | 208.23 M |
Levered Free Cash Flow (TTM) | 8.61 M |
Return on Assets (TTM) | 8.67% |
Return on Equity (TTM) | 23.85% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Amphastar Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | 0.88 |
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Insiders | 22.41% |
% Held by Institutions | 75.14% |
52 Weeks Range | ||
Median | 55.00 (40.52%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Wells Fargo | 22 Nov 2024 | 55.00 (40.52%) | Buy | 45.46 |
No data within this time range.
Date | Type | Details |
---|---|---|
26 Nov 2024 | Announcement | Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference |
13 Nov 2024 | Announcement | Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference |
06 Nov 2024 | Announcement | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 |
29 Oct 2024 | Announcement | Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |